drugset
drugset / Trial / NCT00510029

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00510029 ↗

Phase 1 Completed 72 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupQuadruple-blind

Summary

The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.

Timeline

Start
2007-09
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Danegaptide Peptide — Intravenous

Indications

cardiac rhythm disease